Worg Biotherapeutics

Executive Summary

Worg Biotherapeutics is a global, commercialization-stage biopharmaceutical company focused on developing next-generation specific immunotherapies for allergic and autoimmune diseases. Headquartered in Shanghai, China, the company leverages proprietary platforms, including PCFiT™ and Apitope®, to create molecular allergy immunotherapy (AIT) products. With over 10 products already commercialized in Europe, Worg has established a strong foothold in the allergy diagnostics and therapeutics market. The company's pipeline is advancing through clinical development, targeting both allergy and autoimmune indications. Its integrated approach, combining diagnostics with therapeutics, positions it uniquely to address the growing prevalence of allergic diseases worldwide. Despite its commercial success in Europe, the company remains private, and its valuation is not publicly disclosed. Worg's focus on innovative platforms and expanding global reach makes it a compelling player in the immunology space.

Upcoming Catalysts (preview)

• Q3 2026Regulatory filing in China for lead allergy immunotherapy product70% success
• Q2 2026Initiation of Phase 2 trial for autoimmune disease candidate using Apitope platform50% success
• Q4 2026Partnership deal for commercialization in Asia-Pacific region outside China60% success